Should I buy or sell VYNE Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VYNE Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" VYNE shares. View VYNE analyst ratings or view top-rated stocks .

What is VYNE Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 12 month price objectives for VYNE Therapeutics' shares. Their VYNE share price targets range from $5.75 to $9.00. On average, they anticipate the company's share price to reach $7.38 in the next year. This suggests a possible upside of 220.7% from the stock's current price. View analysts price targets for VYNE or view top-rated stocks among Wall Street analysts .

How have VYNE shares performed in 2024?

VYNE Therapeutics' stock was trading at $2.33 at the beginning of the year. Since then, VYNE shares have decreased by 1.3% and is now trading at $2.30. View the best growth stocks for 2024 here .

Are investors shorting VYNE Therapeutics?

VYNE Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 85,600 shares, an increase of 590.3% from the March 15th total of 12,400 shares. Based on an average daily volume of 125,900 shares, the short-interest ratio is currently 0.7 days. Approximately 0.7% of the shares of the company are sold short. View VYNE Therapeutics' Short Interest .

When is VYNE Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our VYNE earnings forecast .

How were VYNE Therapeutics' earnings last quarter?

VYNE Therapeutics Inc. (NASDAQ:VYNE) issued its quarterly earnings data on Thursday, February, 29th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.30. The company earned $0.08 million during the quarter, compared to the consensus estimate of $0.15 million. VYNE Therapeutics had a negative trailing twelve-month return on equity of 77.46% and a negative net margin of 6,710.38%.

When did VYNE Therapeutics' stock split?

VYNE Therapeutics's stock reverse split on Monday, February 13th 2023. The 1-18 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of VYNE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VYNE Therapeutics investors own include Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , Novan (NOVN) , Organigram (OGI) , Zosano Pharma (ZSAN) , KushCo (KSHB) , Bionano Genomics (BNGO) , Pennsylvania Real Estate Investment Trust (PEI) , Sorrento Therapeutics (SRNE) and Aeterna Zentaris (AEZS) .

How do I buy shares of VYNE Therapeutics?

Shares of VYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VYNE

VYNE Therapeutics (VYNE) Stock Price, News & Analysis

→ This company has increased its dividend every year for 54 years (From DTI) (Ad)

Free VYNE Stock Alerts

$2.30

-0.10 (-4.17%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.25
▼
$2.39
50-Day Range: $1.92
▼
$3.10
52-Week Range: $1.67
▼
$8.73

Volume: 11,091 shs
Average Volume: 166,588 shs
Market Capitalization: $32.43 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.38

Get VYNE Therapeutics alerts:

VYNE Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 220.7% Upside
$7.38 Price Target
Short Interest: Healthy
0.71% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.00) to ($0.96) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.70 out of 5 stars

Medical Sector

423rd out of 919 stocks

Pharmaceutical Preparations Industry

184th out of 403 stocks

3.5

Analyst's Opinion

Consensus Rating
VYNE Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
VYNE Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.71% of the float of VYNE Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
VYNE Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in VYNE Therapeutics has recently increased by 590.32%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
VYNE Therapeutics does not currently pay a dividend.
Dividend Growth
VYNE Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VYNE.

2.4

News and Social Media Coverage

News Sentiment
VYNE Therapeutics has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for VYNE Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for VYNE on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added VYNE Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, VYNE Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.80% of the stock of VYNE Therapeutics is held by insiders.
Percentage Held by Institutions
83.78% of the stock of VYNE Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for VYNE Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.96) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of VYNE Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of VYNE Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
VYNE Therapeutics has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your report

About VYNE Therapeutics Stock (NASDAQ:VYNE)

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

VYNE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VYNE Stock News Headlines

April 13, 2024 | finance.yahoo.com

VYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plans

April 11, 2024 | americanbankingnews.com

Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Increases By 590.3%

April 19, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

March 19, 2024 | finance.yahoo.com

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

March 19, 2024 | globenewswire.com

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

March 7, 2024 | seekingalpha.com

Wall Street Breakfast Podcast: NYCB Gets $1B Investment Boost

March 3, 2024 | finance.yahoo.com

VYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

February 29, 2024 | markets.businessinsider.com

Buy Rating on VYNE Therapeutics: Strong Financials and Promising Clinical Developments

April 19, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

February 29, 2024 | finanznachrichten.de

VYNE Therapeutics Inc.: VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

February 29, 2024 | globenewswire.com

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

February 27, 2024 | finance.yahoo.com

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

February 27, 2024 | globenewswire.com

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

February 21, 2024 | finance.yahoo.com

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

February 21, 2024 | globenewswire.com

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

February 2, 2024 | finance.yahoo.com

Favourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stock

January 10, 2024 | markets.businessinsider.com

Buy Rating for VYNE Therapeutics Backed by Promising Vitiligo Drug Trial Results

January 3, 2024 | finance.yahoo.com

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

November 20, 2023 | msn.com

VYNE Therapeutics says director Lepore buys 13K shares in co

November 14, 2023 | finance.yahoo.com

Cormorant Asset Management, LP Acquires New Stake in VYNE Therapeutics Inc

November 13, 2023 | msn.com

VYNE Therapeutics files to sell 36.27M shares for holders

November 13, 2023 | finanznachrichten.de

VYNE Therapeutics Inc.: VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 13, 2023 | benzinga.com

Recap: VYNE Therapeutics Q3 Earnings

November 13, 2023 | msn.com

VYNE Therapeutics GAAP EPS of -$2.01, revenue of $0.1M

November 13, 2023 | finance.yahoo.com

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 12, 2023 | markets.businessinsider.com

Promising Vitiligo Treatment Trials and Increased Diagnosis Rates Boost VYNE Therapeutics’ Buy Rating: An Overview

November 9, 2023 | investing.com

VYNE Therapeutics secures $88M PIPE deal to advance clinical programs

See More Headlines

Receive VYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VYNE
CUSIP: N/A
CIK: 1566044
Web: vynetherapeutics.com
Phone: (800) 755-7936
Fax: N/A
Employees: 10
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.38
High Stock Price Target: $9.00
Low Stock Price Target: $5.75
Potential Upside/Downside: +220.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($7.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-28,450,000.00
Net Margins: -6,710.38%
Pretax Margin: -6,573.58%
Return on Equity: -77.46%
Return on Assets: -62.93%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.73
Quick Ratio: 12.73

Sales & Book Value

Annual Sales: $420,000.00
Price / Sales: 77.21
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.36 per share
Price / Book: 0.36

Miscellaneous

Outstanding Shares: 14,100,000
Free Float: 13,845,000
Market Cap: $32.43 million
Optionable: Not Optionable
Beta: 1.23

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. David T. Domzalski (Age 57)
CEO, President & Director
Comp: $1.61M
Dr. Iain A. Stuart Ph.D. (Age 51)
Chief Scientific Officer
Comp: $856.82k
Ms. Mutya Harsch J.D. (Age 49)
General Counsel, Chief Legal Officer & Company Secretary
Comp: $817.97k
Mr. Tyler Zeronda (Age 37)
CFO & Treasurer
Dr. Darrell S. Rigel Faad (Age 73)
M.D., Ms, Consultant
Comp: $40.2k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VYNE Stock Analysis - Frequently Asked Questions

Should I buy or sell VYNE Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VYNE Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" VYNE shares.
View VYNE analyst ratings or view top-rated stocks.
What is VYNE Therapeutics' stock price target for 2024?: 1 Wall Street research analysts have issued 12 month price objectives for VYNE Therapeutics' shares. Their VYNE share price targets range from $5.75 to $9.00. On average, they anticipate the company's share price to reach $7.38 in the next year. This suggests a possible upside of 220.7% from the stock's current price.
View analysts price targets for VYNE or view top-rated stocks among Wall Street analysts.
How have VYNE shares performed in 2024?: VYNE Therapeutics' stock was trading at $2.33 at the beginning of the year. Since then, VYNE shares have decreased by 1.3% and is now trading at $2.30.
View the best growth stocks for 2024 here.
Are investors shorting VYNE Therapeutics?: VYNE Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 85,600 shares, an increase of 590.3% from the March 15th total of 12,400 shares. Based on an average daily volume of 125,900 shares, the short-interest ratio is currently 0.7 days. Approximately 0.7% of the shares of the company are sold short.
View VYNE Therapeutics' Short Interest.
When is VYNE Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VYNE earnings forecast.

How were VYNE Therapeutics' earnings last quarter?: VYNE Therapeutics Inc. (NASDAQ:VYNE) issued its quarterly earnings data on Thursday, February, 29th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.30. The company earned $0.08 million during the quarter, compared to the consensus estimate of $0.15 million. VYNE Therapeutics had a negative trailing twelve-month return on equity of 77.46% and a negative net margin of 6,710.38%.
When did VYNE Therapeutics' stock split?: VYNE Therapeutics's stock reverse split on Monday, February 13th 2023. The 1-18 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.
What other stocks do shareholders of VYNE Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other VYNE Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), Organigram (OGI), Zosano Pharma (ZSAN), KushCo (KSHB), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Sorrento Therapeutics (SRNE) and Aeterna Zentaris (AEZS).
How do I buy shares of VYNE Therapeutics?: Shares of VYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VYNE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial